A KRAS-variant as a putative biomarker of ovarian cancer risk

被引：0
|
作者：
Weidhaas, Joanne B.
Slack, Frank
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-1856
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1856
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [1] A KRAS-variant as a biomarker of ovarian cancer risk
    Weidhaas, J. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
    Ratner, Elena
    Lu, Lingeng
    Boeke, Marta
    Barnett, Rachel
    Nallur, Sunitha
    Chin, Lena J.
    Pelletier, Cory
    Blitzblau, Rachel
    Tassi, Renata
    Paranjape, Trupti
    Hui, Pei
    Godwin, Andrew K.
    Yu, Herbert
    Risch, Harvey
    Rutherford, Thomas
    Schwartz, Peter
    Santin, Alessandro
    Matloff, Ellen
    Zelterman, Daniel
    Slack, Frank J.
    Weidhaas, Joanne B.
    CANCER RESEARCH, 2010, 70 (16) : 6509 - 6515
  • [3] The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
    Pilarski, Robert
    Patel, Divya A.
    Weitzel, Jeffrey
    McVeigh, Terri
    Dorairaj, Jemima J.
    Heneghan, Helen M.
    Miller, Nicola
    Weidhaas, Joanne B.
    Kerin, Michael J.
    McKenna, Megan
    Wu, Xifeng
    Hildebrandt, Michelle
    Zelterman, Daniel
    Sand, Sharon
    Shulman, Lee P.
    PLOS ONE, 2012, 7 (05):
  • [4] Estrogen withdrawal, increased breast cancer risk and the KRAS-variant
    McVeigh, Terri P.
    Jung, Song-Yi
    Kerin, Michael J.
    Salzman, David W.
    Nallur, Sunitha
    Nemec, Antonio A.
    Dookwah, Michelle
    Sadofsky, Jackie
    Paranjape, Trupti
    Kelly, Olivia
    Chan, Elcie
    Miller, Nicola
    Sweeney, Karl J.
    Zelterman, Daniel
    Sweasy, Joann
    Pilarski, Robert
    Telesca, Donatello
    Slack, Frank J.
    Weidhaas, Joanne B.
    CELL CYCLE, 2015, 14 (13) : 2091 - 2099
  • [5] The KRAS-variant, multiple breast cancer risk, and estrogen withdrawal
    Weidhaas, Joanne B.
    Mcveigh, Terri
    Pilarski, Robert
    Miller, Nicola
    Sweasy, Joann
    Kerin, Michael
    Nallur, Sunitha
    Sadofsky, Jackie
    Nemec, Antonio
    Sweeney, Karl
    Daniel, Zelterman
    CANCER RESEARCH, 2015, 75
  • [6] The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
    Weidhaas, Joanne B.
    Hu, Chen
    Komaki, Ritsuko
    Masters, Gregory A.
    Blumenschein, George R.
    Chang, Joe Y.
    Lu, Bo
    Dicker, Adam P.
    Bogart, Jeffrey A.
    Garces, Yolanda I.
    Narayan, Samir
    Robinson, Clifford G.
    Kavadi, Vivek S.
    Greenberger, Joel S.
    Koprowski, Christopher D.
    Welsh, James
    Gore, Elizabeth M.
    Macrae, Robert M.
    Paulus, Rebecca
    Bradley, Jeffrey D.
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (10): : 2074 - 2081
  • [7] KRAS variant: a promising biomarker for ovarian cancer outcome
    Miller, Sarah
    PHARMACOGENOMICS, 2012, 13 (02) : 135 - 135
  • [8] Defining the role of a microRNA-based KRAS variant as a biomarker of ovarian cancer risk
    Weidhaas, J.
    Ratner, E.
    Risch, H.
    Lu, L.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S139 - S139
  • [9] A 3′UTR KRAS-variant and triple negative breast cancer
    Paranjape, Trupti
    Weidhaas, Joanne B.
    CANCER RESEARCH, 2011, 71
  • [10] Estrogen withdrawal and breast cancer development in the presence of the KRAS-variant
    Jung, Song-Yi
    Salzman, David
    Weidhaas, Joanne B.
    CANCER RESEARCH, 2015, 75
12345